Core Viewpoint - Credit Agricole experienced a 39% decline in fourth-quarter profit, primarily due to a one-off charge associated with its increased stake in Italy's Banco BPM, alongside rising costs and losses in its operations [1] Financial Performance - The bank reported a significant drop in profit for the fourth quarter, with a 39% decrease compared to previous periods [1] - The decline in profit was influenced by a one-off charge related to the acquisition of a larger stake in Banco BPM [1] Operational Challenges - Rising operational costs have contributed to the overall decline in profitability for Credit Agricole [1] - The bank is facing losses in its various business segments, which further exacerbates the financial challenges [1]

Core Insights - Crédit Agricole Group reported strong financial results for 2025, with revenues of €39,558 million, up 3.9% year-on-year, and net income of €8,754 million, an increase of 1.3% compared to 2024 [1][34][33] - The company plans to increase its dividend to €1.13 per share, reflecting a 3% increase from 2024 [2] - The ACT 2028 Strategic Plan is on track, with a focus on growth across all business lines and a strong emphasis on digitalization and international expansion [3][7] Financial Performance - Revenues for Crédit Agricole S.A. reached €28,079 million, a 3.3% increase from 2024, while operating expenses rose by 4.9% to €15,628 million [1][54] - The cost/income ratio for Crédit Agricole S.A. was 55.7%, up 0.9 percentage points from the previous year, indicating a slight increase in operational efficiency [1][54] - The cost of risk increased by 6.6% to €1,973 million, reflecting a cautious approach to credit risk management [1][35] Customer Growth and Market Position - The Group gained 2.1 million new customers in 2025, with significant growth in retail banking, particularly in France [6][10] - On-balance sheet deposits totaled €847 billion, up 1.2% year-on-year, while outstanding loans reached €895 billion, a 1.7% increase [10][41] - The property and casualty insurance equipment rate rose to 44.7%, indicating a growing customer base in insurance products [10][41] Business Line Performance - The Asset Management division saw net inflows of €21 billion in the fourth quarter, driven by strong performance in both passive and active management [12][64] - Insurance revenues reached €13.1 billion in the fourth quarter, up 20.4% year-on-year, contributing to a record annual revenue of €52.4 billion [59] - Corporate and Investment Banking reported record revenues for both the quarter and the full year, benefiting from strong capital markets activity [14][5] Strategic Initiatives and Future Outlook - Crédit Agricole is set to launch several strategic initiatives in 2026, including a digital savings platform in Germany and enhanced offerings for young customers [16][20] - The Group aims to capture 8 million new customers by 2028, positioning itself as a leading bank for young people and expanding its market share in Europe [19][21] - Continued investment in energy transition financing is a priority, with low-carbon financing exposure increasing significantly [24][25]

Core Insights - The company has released its Q4 2025 financial results, indicating a significant update on its performance and future outlook [1] Financial Performance - The press release provides detailed financial results for Q4 2025, which are accessible through the provided link [1] - The financial results are expected to include key metrics such as revenue, profit margins, and year-over-year growth [1] Future Outlook - The company may outline its strategic initiatives and expectations for the upcoming fiscal year, reflecting on market conditions and potential growth areas [1]

Core Insights - Novartis reported strong performance in 2025 with high single-digit sales growth and core margin expansion despite facing significant US generic competition [3] - Key growth drivers included Kisqali, Kesimpta, Pluvicto, Scemblix, and Cosentyx, which continued their strong trajectory [3] - The company advanced several potential multi-blockbusters in its pipeline with FDA approvals and positive Phase III readouts [3] - Novartis expects to grow through the largest patent expiry in its history in 2026, indicating the strength of its business [3] Financial Performance - Q4 2025 net sales reached USD 13.3 billion, a 1% increase year-over-year, while full-year net sales were USD 54.5 billion, reflecting an 8% increase [4][13] - Operating income for Q4 was USD 3.6 billion, up 2%, and for the full year, it was USD 17.6 billion, a 21% increase [10][13] - Net income for Q4 was USD 2.4 billion, down 15%, while full-year net income was USD 14.0 billion, up 17% [10][14] - Core operating income for Q4 was USD 4.9 billion, a 1% increase, and for the full year, it was USD 21.9 billion, a 12% increase [11][16] - Free cash flow for Q4 was USD 1.7 billion, down 54%, while for the full year, it was USD 17.6 billion, an 8% increase [12][17] Key Growth Drivers - Priority brands showed strong performance in Q4, with Kisqali sales growing 44%, Kesimpta 27%, Pluvicto 70%, Scemblix 87%, and Cosentyx 11% [18] - The top 20 brands contributed to a total of USD 10.8 billion in Q4 sales, with a slight increase of 2% year-over-year [19] R&D and Innovation - Novartis received FDA approval for Itvisma, the first gene replacement therapy for a broad SMA population, and expanded indications for Scemblix [21] - Pluvicto's FDA submission for metastatic hormone-sensitive prostate cancer was completed based on Phase III data [22] - Ongoing trials for ianalumab showed significant benefits in Sjögren's disease and primary immune thrombocytopenia [23][24] Strategic Initiatives - Novartis announced a proposed acquisition of Avidity Biosciences, expected to close in the first half of 2026, enhancing its pipeline in neuroscience [25] - The company reached an agreement with the US government to lower drug prices, which will impact its 2026 guidance [32] Capital Structure - Novartis repurchased 77.6 million shares for USD 8.9 billion in 2025, reducing the total number of shares outstanding by 66.9 million [27] - Net debt increased to USD 21.9 billion by the end of 2025, primarily due to cash outflows for share repurchases and dividends [28] 2026 Guidance - For 2026, Novartis expects low single-digit growth in net sales and a decline in core operating income [30]

Core Viewpoint - TGS has secured an ocean bottom node (OBN) contract in Europe, which will enhance its data acquisition campaign for the 2026 season [1][2]. Group 1: Contract Details - The OBN contract has a duration of approximately 45 days, with acquisition activities set to begin in early April [1]. - The contract is aimed at optimizing resource extraction over a well-established producing field for a repeat customer [2]. Group 2: Company Insights - TGS is recognized as a leading provider of energy data and intelligence, offering advanced technology and solutions across the entire energy value chain [3]. - The company emphasizes its commitment to acquiring and delivering high-quality data, which supports clients in making informed decisions in the energy sector [2][3].

Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium - February 4th, 2026, 07.00 hrs CET Dear, Please find herewith the link to our most recent press release: https://www.melexis.com/en/news/2026/financial/melexis-q4-2025-results Attachment ...

Core Insights - NORBIT will announce its fourth quarter results for 2025 on February 11, 2026, with the interim report and presentation materials available from 07:00 am CET [1] - The results will be presented by CEO Per Jørgen Weisethaunet and CFO Per Kristian Reppe at 09:00 am CET [2] - NORBIT is a global provider of tailored technology, structured into three business segments: Oceans, Connectivity, and Product Innovation & Realization [2] Company Overview - NORBIT focuses on solving challenges and promoting sustainability through innovative solutions, aligning with its mission to "Explore More" [2] - The Oceans segment delivers technology solutions to global maritime markets, while the Connectivity segment provides wireless solutions for identification, monitoring, and tracking [2] - The Product Innovation & Realization segment offers R&D services, proprietary products, and contract manufacturing to key customers [2] - The company is headquartered in Trondheim, has around 650 employees, and operates manufacturing facilities in Europe and North America [2]

Borregaard’s operating revenues increased to NOK 1,833 million (NOK 1,744 million)2 in the 4th quarter of 2025. EBITDA1 was NOK 405 million (NOK 398 million). The result in BioMaterials increased, while BioSolutions and Fine Chemicals had lower results compared with the 4th quarter of 2024. In BioSolutions, high deliveries of biovanillin and sustained growth in sales to agriculture were more than offset by increased costs. For BioMaterials, higher sales prices and lower wood and energy costs, more than comp ...

Core Insights - The P&C reinsurance market remains competitive, with SCOR achieving a targeted growth of 4.7% in traditional reinsurance and a significant 80.5% growth in Alternative Solutions during the January 2026 renewals [2][4]. Market Overview - Demand for reinsurance coverage is high, but competition has intensified due to strong profits and increased capital supply, leading to price reductions in most lines, particularly non-proportional placements [3][4]. - The P&C reinsurance book renewed on January 1, 2026, totaled EUR 4,493 million, reflecting a 4.7% increase compared to January 2024, with P&C Lines growing by 7.4% and Specialty Lines by 0.3% [3][4]. Company Performance - SCOR's net underwriting ratio is expected to increase by 2.0 percentage points, supported by retrocession buying [2][4]. - The growth in P&C Lines is attributed to a flight-to-quality trend, particularly in APAC and North America, and strong relationships with core clients [4]. - The company maintains disciplined underwriting practices, which contribute to active portfolio steering and margin protection in Specialty Lines [4]. Future Outlook - SCOR is prepared for continued competition in the reinsurance market and will pursue its Forward 2026 diversified growth strategy in a disciplined manner [5].

Amundi launches a 500 million euros share buyback programme  As announced during the publication of its 2025 annual results, Amundi announces today the launch of a 500 million euros share buyback programme. Amundi has mandated an independent investment services provider to carry out the share buyback programme on its behalf, for a total amount of €500 million (accounting for circa 3.1% of Amundi’s share capital at current price levels). The buyback programme will start on 4 February 2026 and end no later t ...